Semaglutide for Type 2 Diabetes and Stroke Risk
Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes
Recruiting
Phase 4
Interventional Study
Diabetes Mellitus, Type 2
Stroke (CVA) or Transient Ischemic Attack
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 40 – 65
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Screening
- Participants needed
- 50 (estimated)
- Sponsor
- University of Washington · Other
Who this trial is looking for
This trial is looking for adults with type 2 diabetes to study the effects of semaglutide on blood flow in the brain. Participants will either receive semaglutide or a placebo and have MRI scans taken over one year.
Are You a Good Fit for This Trial?
You may be able to join if
- I am between 40 and 65 years old
- I have been diagnosed with type 2 diabetes for at least 3 years
- My HbA1C is between 7% and 10%
- I am using medications for blood sugar control
- I am medically stable
- I have not taken any investigational drug in the past 6 months
- I am willing to participate and sign the consent form
You may not be able to join if
- I cannot have an MRI or contrast agent
- My kidney function (eGFR) is below 45 mL/min/1.73m2
- I am currently treated with a GLP-1 receptor antagonist
- I cannot monitor my blood glucose at home
- I take more than 100 units of insulin daily
- I have uncontrolled high blood pressure
- My LDL cholesterol is above 130 mg/dL and I'm not on stable statin therapy
- I have a history of pancreatitis
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
A human subjects research study, the primary purpose of which is to assess the EFFECTS OF SEMAGLUTIDE ON INTRACRANIAL BLOOD FLOW AND BLOOD-BRAIN BARRIER PERMEABILITY IN TYPE-2 DIABETES (T2D) through testing of the intervention on patients in a clinical setting. The study will randomize subjects with diabetes to either semaglutide or matching placebo. Magnetic resonance images will be primary endpo…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Men and women 40-65 years of age
2. Subjects with type-2 diabetes \>= 3 years and HbA1C 7%-10% with blood sugar control medications including insulin, metformin, sulfonylureas, or SGLT2 inhibitors
3. Medically stable
4. Has not received any investigational drug in the past 6 …
Contacts